The term off-label describes an approved drug used outside its approved labeling [4]. The product, intended use and patient population all matter. A missing diabetes diagnosis alone cannot tell you whether a prescription was off-label. Some products are approved for weight management.
Prescribing after a PCOS diagnosis
Studies of GLP-1 treatment and PCOS ask a different question from the studies that count prescriptions. In one Polish private network, 5.97% of women diagnosed with PCOS in 2024 started an incretin drug within a year, up from 0.14% in 2018. Each later calendar year was associated with higher odds of starting treatment (adjusted odds ratio 1.64, 95% CI 1.56–1.73) [1].
Across the cohort, 11.5% of incretin users had coded type 2 diabetes and 75.5% also had a record of metformin exposure. Incretin users had a higher median BMI than women who took only metformin or received neither treatment. These records describe prescribing patterns and cannot establish effects on ovulation, fertility or other PCOS outcomes [1].
Use around childbirth and among young people
A U.S. study found that prescribing in the year after delivery rose from 0.3 to 14.6 per 1,000 deliveries between 2019 and 2024. The year before delivery includes time before pregnancy, so prescriptions recorded during that window cannot all be attributed to use in pregnancy [2].
Danish registry data showed 418 new users per 100,000 people aged 12 to 24 in 2025, up from 8.4 in 2018. The study attributed much of the growth to semaglutide for weight management. To study how long people stay on a GLP-1, the researchers measured how long prescriptions covered patients. They found that 38% still had coverage after a year, but the records could not explain why people stopped[3].